Trevi Therapeutics Execs to Present at Key August Conferences
Event summary
- Trevi Therapeutics execs to present at Oppenheimer's Biotech in the Berkshires (Aug 4) and Stifel's Biotech Summer Summit (Aug 10-12).
- CEO Jennifer Good and CFO David Hastings scheduled for fireside chat at Stifel event.
- Haduvio™ (oral nalbuphine ER) remains investigational with no FDA approval yet.
- Company targets chronic cough in IPF, non-IPF ILD, and refractory chronic cough markets.
The big picture
Trevi Therapeutics is positioning itself as a key player in the chronic cough treatment space, targeting both IPF-related and refractory chronic cough indications. The upcoming conference presentations come at a critical time as the company seeks to build investor confidence ahead of potential regulatory milestones for Haduvio. With no FDA-approved therapies currently available for these conditions, Trevi has an opportunity to capture significant market share if it can successfully navigate the regulatory pathway.
What we're watching
- Regulatory Pathway
- Whether Trevi can secure FDA approval for Haduvio given the high unmet need in chronic cough indications.
- Market Positioning
- How Trevi differentiates itself in a competitive landscape with no current FDA-approved therapies for these conditions.
- Clinical Data
- The pace at which additional clinical data will be released to support Haduvio's efficacy and safety profile.
Related topics